Commentary|Articles|December 13, 2024
Curating Depression Treatments Using Biomarker-Based Selection
Author(s)Rudolf Uher, MUDr, PhD
What if biomarkers could tell you whether or not a depression treatment would work before a patient started?
Advertisement
At the 63rd Annual Meeting of the American College of Neuropsychopharmacology, Rudolf Uher MUDr, PhD, spoke with Psychology Times about research being done at Dalhousie University testing biomarker-based selection of treatment. Patients with depression take an initial assessment and are prescribed treatment based on the assessment.
Uher said some patients start only with an antidepressant while others receive the antidepressant and an add-on adjunctive treatment.
Dr Uher is a psychiatrist and professor in the Department of Psychiatry at Dalhousie University in Nova Scotia, Canada.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
Experience With Xanomeline/Trospium in an Acute Inpatient Setting Treating Individuals With Schizophrenia
2
Brain Trust: Carl Salzman, MD, on Benzodiazepine Mindful Prescribing, Misuse, and Dependence
3
DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial
4
Phase 4 Trial of Viloxazine ER Shows Real-World Gains for ADHD With Comorbid Depression, Anxiety
5